```
=> d his

     (FILE 'HOME' ENTERED AT 13:28:11 ON 25 SEP 2006)

     FILE 'EMBASE' ENTERED AT 13:28:19 ON 25 SEP 2006
L1        10064 S GANGLIOSIDE
L2          391 S L1 AND (SEPARATION OR PURIFICATION)
L3           31 S L2 AND HYDROLYSIS
L4           23 S L3 NOT PY>2001

     FILE 'USPATFULL' ENTERED AT 13:32:30 ON 25 SEP 2006
L5         3003 S GANGLIOSIDE
L6            9 S L1 AND (SEPARATION/TI OR PURIFICATION/TI)

     FILE 'REGISTRY' ENTERED AT 13:36:55 ON 25 SEP 2006
L7               STRUCTURE UPLOADED
L8            4 S L7
L9           33 S L7 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:39:10 ON 25 SEP 2006
L10         307 S L9
L11           7 S L10 AND GLYCOSYLATION
L12           1 S L9 AND LECITHIN

     FILE 'BIOSIS, EMBASE' ENTERED AT 13:41:52 ON 25 SEP 2006
L13          18 S LECITHIN AND GLYCOSPHINGO?
L14           0 S L13 AND HYDROLYSIS
L15           4 S L13 AND (SEPARATION OR ISOLATION OR PURIFICATION)

     FILE 'USPATFULL' ENTERED AT 13:43:21 ON 25 SEP 2006
L16        1616 S GLYCOSPHINGO?
L17           5 S L16 AND (PURIFIACTION/TI OR SEPARATIOM/TI OR ISOLATION/TI)
L18           9 S L16 AND (PURIFICATION/TI OR SEPARATION/TI OR ISOLATION/TI)
L19           5 S L18 AND HYDROLYSIS

     FILE 'REGISTRY' ENTERED AT 13:59:56 ON 25 SEP 2006
L20              STRUCTURE UPLOADED
L21           0 S L20
L22          20 S L20 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:01:10 ON 25 SEP 2006
L23           6 S L22

     FILE 'REGISTRY' ENTERED AT 14:15:37 ON 25 SEP 2006

     FILE 'CAPLUS' ENTERED AT 14:27:49 ON 25 SEP 2006
L24          10 S L9 AND GLYCOSYLAT?

     FILE 'REGISTRY' ENTERED AT 14:31:07 ON 25 SEP 2006
L25           1 S PARAGLOBOSIDE/CN

     FILE 'CAPLUS' ENTERED AT 14:31:30 ON 25 SEP 2006
L26         270 S L25
L27           7 S L25/THU
L28           8 S L25/PREP
L29           7 S L26 AND ISOLATION
L30           5 S L26 AND ISOLATION/TI

     FILE 'REGISTRY' ENTERED AT 15:11:44 ON 25 SEP 2006
L31              STRUCTURE UPLOADED
L32           1 S L31 FAM FULL

     FILE 'CAPLUS' ENTERED AT 15:12:16 ON 25 SEP 2006
L33           1 S L32
```

```
     FILE 'REGISTRY' ENTERED AT 15:12:53 ON 25 SEP 2006
L34            1 S GABAPENTIN/CN

     FILE 'CAPLUS' ENTERED AT 15:13:10 ON 25 SEP 2006
L35         1404 S L34
L36         1069 S L34/THU
L37           27 S L36 AND (OSTEOARTHRITIS OR (CARTILAGE))
L38            0 S L37 NOT PY>2000
L39            1 S L37 NOT PY>2002
L40            7 S L36 AND CARTILAGE
```

=>
Uploading C:\Program Files\Stnexp\Queries\10602413verify.str



chain nodes :
7 8 9 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
ring nodes :
1 2 3 4 5 6 10 11 12 13 14
chain bonds :
1-23 1-24 2-25 2-26 3-27 3-28 4-29 4-30 5-7 5-20 6-21 6-22 7-8 7-10
7-17 8-9 8-18 8-19 11-15 12-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 10-11 10-14 11-12 12-13 12-16 13-14
exact bonds :
1-23 1-24 2-25 2-26 3-27 3-28 4-29 4-30 5-7 5-20 6-21 6-22 7-8 7-10
7-17 8-18 8-19 11-15

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS

L31 STRUCTURE UPLOADED

=> d l31
L31 HAS NO ANSWERS
L31 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l31 fam full
FULL SEARCH INITIATED 15:12:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       16 TO ITERATE

100.0% PROCESSED       16 ITERATIONS                                  1 ANSWERS
SEARCH TIME: 00.00.01

L32            1 SEA FAM FUL L31

=> d l32

L32  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   758697-34-6  REGISTRY
ED   Entered STN:  08 Oct 2004
CN   1,2,4-Oxadiazol-5(2H)-one, 3-(2-amino-1-cyclohexylethyl)- (9CI)  (CA INDEX
     NAME)
MF   C10 H17 N3 O2
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL
```





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	67.59	558.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.25

FILE 'CAPLUS' ENTERED AT 15:12:16 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l32
L33 1 L32

=> d l33 ti abs bib

L33 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of tetrazole and oxadiazolone substituted β-amino acid derivatives as ligands of the α2δ-subunit of a calcium channel
AB Title compds. R2R1(NH2)C-C(G)R3R4 [G = tetrazolyl, 1,3,5-oxadiazol-2-one; R1-2 = H, alkyl, alkoxy, etc.; R3-4 = H, Me; (I)] and related cyclopropane derivs. are prepared For instance, 4-methyl-2-(1H-tetrazol-5-yl)pentylamine is prepared from 1-benzyl-1H-tetrazole and 4-methyl-1-nitropentene in 2 steps. Selected example compds. exhibit binding with nM to μM affinity for α2δ-subunit of the calcium channel (3 biol. examples). I are useful for the treatment of central nervous system and other disorders.
AN 2004:756699 CAPLUS <<LOGINID::20060925>>
DN 141:277627
TI Preparation of tetrazole and oxadiazolone substituted β-amino acid derivatives as ligands of the α2δ-subunit of a calcium channel
IN Barta, Nancy Sue; Colbry, Norman Lloyd; Hudack, Raymond Andrew, Jr.; Lin, Kristin Knapp; Schwarz, Jacob Bradley; Thorpe, Andrew John; Wustrow, David Juergen; Zhu, Zhijian
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent

```
LA   English
FAN.CNT 1
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
PI   WO 2004078734          A1    20040916    WO 2004-IB510            20040223
     WO 2004078734          C1    20051215
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     CA 2518218             AA    20040916    CA 2004-2518218          20040223
     EP 1603890             A1    20051214    EP 2004-713604           20040223
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2004008110          A     20060301    BR 2004-8110             20040223
     JP 2006519831          T2    20060831    JP 2006-506264           20040223
     US 2005014804          A1    20050120    US 2004-795760           20040308
PRAI US 2003-452871P        P     20030307
     WO 2004-IB510          W     20040223
OS   MARPAT 141:277627
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      3.20     562.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                        ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -0.75     -18.00

FILE 'REGISTRY' ENTERED AT 15:12:53 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 SEP 2006  HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES:  24 SEP 2006  HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html
```

```
=> s gabapentin/cn
L34           1 GABAPENTIN/CN

=> d l34

L34  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   60142-96-3  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1-(Aminomethyl)cyclohexaneacetic acid
CN   CI 945
CN   Gabapentin
CN   Go 3450
CN   GOE 2450
CN   GOE 3450
CN   Neurontin
MF   C9 H17 N O2
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
       DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
       IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT,
       PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2,
       USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          1401 REFERENCES IN FILE CA (1907 TO DATE)
            46 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          1404 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     7.10     569.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -18.00

FILE 'CAPLUS' ENTERED AT 15:13:10 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l34
L35          1404 L34

=> s l34/thu
             1404 L34
           814465 THU/RL
L36          1069 L34/THU
                  (L34 (L) THU/RL)

=> s l36 and (osteoarthritis or (cartilage))
             8177 OSTEOARTHRITIS
            25383 CARTILAGE
L37            27 L36 AND (OSTEOARTHRITIS OR (CARTILAGE))

=> s l37 not py>2000
          6290614 PY>2000
L38              0 L37 NOT PY>2000

=> d l37 1-27 ti

L37  ANSWER 1 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   1,3-Disubstituted heteroaryl derivatives as NMDA/NR2B antagonists, their
     preparation, pharmaceutical compositions, and use in therapy

L37  ANSWER 2 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of nitroxyalkyl derivatives of phenol for treating
     inflammatory, cardiovascular and peripheral vascular diseases

L37  ANSWER 3 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Novel dosage form comprising modified-release and immediate-release active
     ingredients

L37  ANSWER 4 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   The Effects of Diacerhein on Mechanical Allodynia in Inflammatory and
     Neuropathic Models of Nociception in Mice

L37  ANSWER 5 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Crystalline polymorphs of a CXC-chemokine receptor ligand

L37  ANSWER 6 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor
     ligands

L37  ANSWER 7 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of diaminothiadiazoles as CXC- and CC-chemokine receptor
     ligands

L37  ANSWER 8 OF 27  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method of biochemical treatment of persistent pain by inhibiting
```

biochemical mediators of inflammation

L37 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification, and management of pain

L37 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising selective cytokine inhibitory drug for treatment, modification and management of pain

L37 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions treatment of chronic inflammatory diseases

L37 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor

L37 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Adenosine derivatives for the treatment of pain

L37 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities

L37 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treatment of pain with spongosine

L37 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain

L37 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions using selective cytokine inhibitory drugs, alone or in combination with other therapeutic means, for treatment, modification and management of pain

L37 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain

L37 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2

L37 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tetracycline compounds having target therapeutic activities

L37 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Treating nerve pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels (HCN)

L37 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chondroprotective/restorative compositions containing hyaluronic acid

L37 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of treating cartilage damage

L37 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors

L37 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of using and compositions comprising (+)-sibutramine optionally in combination with other pharmacologically active compounds

L37 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds

L37 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2006 ACS on STN
TI Isobutyl-GABA and its derivatives for the treatment of pain

=> s l37 not py>2002
4373464 PY>2002
L39 1 L37 NOT PY>2002

=> d l39 ti abs bib

L39 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor. A solution of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in Et acetate was added to a solution of 12.3 g racemic sibutramine in Et acetate and the reaction mixture was heated to reflux and cooled to room temperature The white precipitate was collected and the solid was then
suspended in Et acetate and heated at reflux for 30 min. The solid was collected and further crystallized in iso-Pr alc. to give 11.3 g of (-)-sibutramine L-DBTA (yield 76%). Free base was obtained by treatment of (-)-sibutramine L-DBTA with saturated aqueous NaHCO3 and extracted with chloroform.
A pharmacol. study was conducted to determine the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixture of sibutramine. A capsule contained (-) sibutramine 10.0, lactose 70.0, corn starch 19.5, and magnesium stearate 0.05 mg.
AN 2002:51988 CAPLUS <<LOGINID::20060925>>
DN 136:107551
TI Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
IN Young, James W.; Jerussi, Thomas P.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 721,669.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002006963	A1	20020117	US 2001-770665	20010129
WO 2002060428	A2	20020808	WO 2002-US2039	20020123
WO 2002060428	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

```
            UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 1992-903040       B1    19920623
    US 1995-461608        B1    19950605
    US 2000-721669        A2    20001127
    US 2001-770665        A     20010129


=> s l36 and cartilage
         25383 CARTILAGE
L40          7 L36 AND CARTILAGE

=> d l40 1-7 ti

L40  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Novel dosage form comprising modified-release and immediate-release active
     ingredients

L40  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Combination of an allosteric inhibitor of matrix metalloproteinase-13 and
     a ligand to an alpha-2-delta receptor

L40  ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Tetracycline compounds having target therapeutic activities

L40  ANSWER 4 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Combinations of an alpha-2-delta ligand with a selective inhibitor of
     cyclooxygenase-2

L40  ANSWER 5 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Tetracycline compounds having target therapeutic activities

L40  ANSWER 6 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Chondroprotective/restorative compositions containing hyaluronic acid

L40  ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Method of treating cartilage damage
```